Translational Mini-Review Series on Immunology of Vascular Disease: Accelerated atherosclerosis in vasculitis

Clinical and Experimental Immunology

Volumn 156, Issue 3, 2009, Pages 377-385

  Cohen Tervaert, J W ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

ANCA; Atherosclerosis; MPO; Ox LDL antibodies; Vasculitis

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; METHOTREXATE; MYELOBLASTIN; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; OXIDIZED LOW DENSITY LIPOPROTEIN ANTIBODY; STEROID; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ANTIBODY;

ANAPHYLACTOID PURPURA; AORTA ARCH SYNDROME; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CD4+ CD28- T LYMPHOCYTE; CHURG STRAUSS SYNDROME; CLINICAL FEATURE; CRYOGLOBULINEMIA; DENDRITIC CELL; DIABETES MELLITUS; DRUG MEGADOSE; ENDOTHELIAL DYSFUNCTION; GIANT CELL ARTERITIS; HUMAN; HYPERTENSION; INFLAMMATORY DISEASE; ISCHEMIC HEART DISEASE; LEUKOCYTOCLASTIC VASCULITIS; MICROSCOPIC POLYANGIITIS; MORTALITY; MUCOCUTANEOUS LYMPH NODE SYNDROME; PATHOPHYSIOLOGY; POLYARTERITIS NODOSA; PRIORITY JOURNAL; PROTEINURIA; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; STEROID THERAPY; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE SUBPOPULATION; VASCULITIS; WEGENER GRANULOMATOSIS;

ATHEROSCLEROSIS; AUTOANTIBODIES; DISEASE PROGRESSION; HUMANS; T-LYMPHOCYTES; VASCULITIS;

EID: 66149138018     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2009.03885.x     Document Type: Review

References (101)

1. Libby P. The molecular mechanisms of the thrombotic complications of atherosclerosis. J Intern Med 2008 263 : 517 27.
2. Thim T, Hagensen MK, Bentzon JF, Falk E. From vulnerable plaque to atherothrombosis. J Intern Med 2008 263 : 506 16.
3. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005 352 : 1685 95.
4. Nilsson J, Hansson GK. Autoimmunity in atherosclerosis: a protective response losing control? J Intern Med 2008 263 : 464 78.
5. Taleb S, Tedgui A, Mallat Z. Regulatory T-cell immunity and its relevance to atherosclerosis. J Intern Med 2008 263 : 489 99.
6. Shoenfeld Y, Wu R, Dearing LD, Matsuura E. Are anti-oxidized low-density lipoprotein antibodies pathogenic or protective? Circulation 2004 110 : 2552 8. (Pubitemid 39453000)
7. Wolfe F, Mitchell DM, Sibley JT et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994 37 : 481 94. (Pubitemid 24115934)
8. Naz SM, Symmons DP. Mortality in established rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007 21 : 871 83. (Pubitemid 47377805)
9. Peters MJ, van Halm VP, Nurmohamed MT et al. Relations between autoantibodies against oxidized low-density lipoprotein, inflammation, subclinical atherosclerosis, and cardiovascular disease in rheumatoid arthritis. J Rheumatol 2008 35 : 1495 9.
10. Haque S, Mirjafari H, Bruce IN. Atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Curr Opin Lipidol 2008 19 : 338 43.
11. van Halm VP, Peters MJ, Voskuyl AE et al. Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease, a cross sectional study. The CARRE Investigation. Ann Rheum Dis 2008.
12. Manzi S, Meilahn EN, Rairie JE et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997 145 : 408 15. (Pubitemid 27084212)
13. Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976 60 : 221 5.
14. Bjornadal L, Yin L, Granath F, Klareskog L, Ekbom A. Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-95. J Rheumatol 2004 31 : 713 19. (Pubitemid 38451257)
15. Frostegard J. SLE, atherosclerosis and cardiovascular disease. J Intern Med 2005 257 : 485 95. (Pubitemid 40776508)
16. Shoenfeld Y, Gerli R, Doria A et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005 112 : 3337 47. (Pubitemid 41717573)
17. Giles JT, Post W, Blumenthal RS, Bathon JM. Therapy insight: managing cardiovascular risk in patients with rheumatoid arthritis. Nat Clin Pract Rheumatol 2006 2 : 320 9. (Pubitemid 43842261)
18. Sitia S, Atzeni F, Sarzi-Puttini P et al. Cardiovascular involvement in systemic autoimmune diseases. Autoimmun Rev 2009 8 : 281 6.
19. Maugeri N, Rovere-Querini P, Baldini M, Sabbadini MG, Manfredi AA. Translational Mini-Review Series on Immunology of Vascular Disease: Mechanisms of vascular inflammation and remodelling in systemic vasculitis. Clin Exp Immunol doi: 10.1111/j.1365-2249.2009.03921.x.
20. Jennette JC, Falk RJ, Andrassy K et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994 37 : 187 92. (Pubitemid 24065492)
21. Cohen Tervaert JW, Stegeman CA, Kallenberg CG. Standard therapeutic regimens for vasculitis. Birkhauser Verlag Basel/Switzerland, 2001.
22. Mahr AD, Jover JA, Spiera RF et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 2007 56 : 2789 97. (Pubitemid 47237299)
23. Matteson EL, Gold KN, Bloch DA, Hunder GG. Long-term survival of patients with giant cell arteritis in the American College of Rheumatology giant cell arteritis classification criteria cohort. Am J Med 1996 100 : 193 6. (Pubitemid 26062514)
24. Gonzalez-Gay MA, Blanco R, Abraira V et al. Giant cell arteritis in Lugo, Spain, is associated with low longterm mortality. J Rheumatol 1997 24 : 2171 6. (Pubitemid 27474039)
25. Gonzalez-Gay MA, Rubiera G, Pineiro A et al. Ischemic heart disease in patients from Northwest Spain with biopsy proven giant cell arteritis. A population based study. J Rheumatol 2005 32 : 502 6. (Pubitemid 40381422)
26. Gonzalez-Juanatey C, Llorca J, Garcia-Porrua C, Sanchez-Andrade A, Martin J, Gonzalez-Gay MA. Steroid therapy improves endothelial function in patients with biopsy-proven giant cell arteritis. J Rheumatol 2006 33 : 74 8. (Pubitemid 43054283)
27. Gonzalez-Gay MA. Glucocorticoid-related cardiovascular and cerebrovascular events in rheumatic diseases: myth or reality? Arthritis Rheum 2007 57 : 191 2. (Pubitemid 47164078)
28. Gonzalez-Juanatey C, Lopez-Diaz MJ, Martin J, Llorca J, Gonzalez-Gay MA. Atherosclerosis in patients with biopsy-proven giant cell arteritis. Arthritis Rheum 2007 57 : 1481 6. (Pubitemid 350308847)
29. Filer A, Nicholls D, Corston R, Carey P, Bacon P. Takayasu arteritis and atherosclerosis: illustrating the consequences of endothelial damage. J Rheumatol 2001 28 : 2752 3. (Pubitemid 33135668)
30. Seyahi E, Ugurlu S, Cumali R et al. Atherosclerosis in Takayasu arteritis. Ann Rheum Dis 2006 65 : 1202 7. (Pubitemid 44277397)
31. Rav-Acha M, Plot L, Peled N, Amital H. Coronary involvement in Takayasu's arteritis. Autoimmun Rev 2007 6 : 566 71. (Pubitemid 47374620)
32. Numano F, Okawara M, Inomata H, Kobayashi Y. Takayasu's arteritis. Lancet 2000 356 : 1023 5.
33. Raninen RO, Kupari MM, Hekali PE. Carotid and femoral artery stiffness in Takayasu's arteritis. An ultrasound study. Scand J Rheumatol 2002 31 : 85 8. (Pubitemid 34518086)
34. Noto N, Okada T, Yamasuge M et al. Noninvasive assessment of the early progression of atherosclerosis in adolescents with Kawasaki disease and coronary artery lesions. Pediatrics 2001 107 : 1095 9. (Pubitemid 32440617)
35. Cheung YF, Wong SJ, Ho MH. Relationship between carotid intima-media thickness and arterial stiffness in children after Kawasaki disease. Arch Dis Child 2007 92 : 43 7. (Pubitemid 46132933)
36. Ikemoto Y, Ogino H, Teraguchi M, Kobayashi Y. Evaluation of preclinical atherosclerosis by flow-mediated dilatation of the brachial artery and carotid artery analysis in patients with a history of Kawasaki disease. Pediatr Cardiol 2005 26 : 782 6. (Pubitemid 43130170)
37. McCrindle BW, McIntyre S, Kim C, Lin T, Adeli K. Are patients after Kawasaki disease at increased risk for accelerated atherosclerosis? J Pediatr 2007 151 : 244 8, 8 e1. (Pubitemid 47284131)
38. Cohen Tervaert JW, Van Paassen P, Damoiseaux J. Type II cryoglobulinemia is not associated with hepatitis C infection: the Dutch experience. Ann NY Acad Sci 2007 1107 : 251 8. (Pubitemid 47528802)
39. Kallenberg CG, Brouwer E, Weening JJ, Tervaert JW. Anti-neutrophil cytoplasmic antibodies: current diagnostic and pathophysiological potential. Kidney Int 1994 46 : 1 15. (Pubitemid 24210431)
40. Hedger N, Stevens J, Drey N, Walker S, Roderick P. Incidence and outcome of pauci-immune rapidly progressive glomerulonephritis in Wessex, UK: a 10-year retrospective study. Nephrol Dial Transplant 2000 15 : 1593 9.
41. Westman KW, Selga D, Isberg PE, Bladstrom A, Olsson H. High proteinase 3-anti-neutrophil cytoplasmic antibody (ANCA) level measured by the capture enzyme-linked immunosorbent assay method is associated with decreased patient survival in ANCA-associated vasculitis with renal involvement. J Am Soc Nephrol 2003 14 : 2926 33. (Pubitemid 37305655)
42. McLaughlin K, Jerimiah P, Fox JG, Mactier RA, Simpson K, Boulton-Jones JM. Has the prognosis for patients with pauci-immune necrotizing glomerulonephritis improved? Nephrol Dial Transplant 1998 13 : 1696 701. (Pubitemid 28306797)
43. Allen A, Pusey C, Gaskin G. Outcome of renal replacement therapy in antineutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 1998 9 : 1258 63. (Pubitemid 28283889)
44. Gayraud M, Guillevin L, le Toumelin P et al. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 2001 44 : 666 75. (Pubitemid 32234626)
45. Grotz W, Wanner C, Keller E et al. Crescentic glomerulonephritis in Wegener's granulomatosis: morphology, therapy, outcome. Clin Nephrol 1991 35 : 243 51.
46. Slot MC, Tervaert JW, Franssen CF, Stegeman CA. Renal survival and prognostic factors in patients with PR3-ANCA associated vasculitis with renal involvement. Kidney Int 2003 63 : 670 7. (Pubitemid 36126814)
47. Franssen CF, Stegeman CA, Oost-Kort WW et al. Determinants of renal outcome in anti-myeloperoxidase-associated necrotizing crescentic glomerulonephritis. J Am Soc Nephrol 1998 9 : 1915 23. (Pubitemid 28443489)
48. Aasarod K, Iversen BM, Hammerstrom J, Bostad L, Vatten L, Jorstad S. Wegener's granulomatosis: clinical course in 108 patients with renal involvement. Nephrol Dial Transplant 2000 15 : 611 8. (Pubitemid 30242977)
49. Zaenker M, Aries PM, Herlyn K, Lamprecht P, Bacon PA, Gross WL. Accelerated atherosclerosis in Wegener's granulomatosis (WG): a sonographic case-control study on intima media thickness. Arthritis Rheum 2002 46 : S35.
50. McLaren JS, Salisbury EM, Jayne DR, Luqmani RA. Cardiovascular disease incidence and risk factors in ANCA-associated primary systemic vasculitis (AASV). Kidney Bloodpressure Res 2003 26 : 282.
51. de Leeuw K, Sanders JS, Stegeman C, Smit A, Kallenberg CG, Bijl M. Accelerated atherosclerosis in patients with Wegener's granulomatosis. Ann Rheum Dis 2005 64 : 753 9. (Pubitemid 41362766)
52. Chironi G, Pagnoux C, Simon A et al. Increased prevalence of subclinical atherosclerosis in patients with small-vessel vasculitis. Heart 2007 93 : 96 9. (Pubitemid 46094064)
53. Raza K, Thambyrajah J, Townend JN et al. Suppression of inflammation in primary systemic vasculitis restores vascular endothelial function: lessons for atherosclerotic disease? Circulation 2000 102 : 1470 2.
54. Booth AD, Jayne DR, Kharbanda RK et al. Infliximab improves endothelial dysfunction in systemic vasculitis: a model of vascular inflammation. Circulation 2004 109 : 1718 23. (Pubitemid 38198843)
55. Bruce IN, Harris CM, Nugent A, McDermott BJ, Johnston GD, Bell AL. Enhanced endothelium-dependent vasodilator responses in patients with systemic vasculitis. Scand J Rheumatol 1997 26 : 318 24. (Pubitemid 27390764)
56. Nienhuis HL, de Leeuw K, Smit AJ et al. Enhanced endothelium-dependent microvascular responses in patients with Wegener's granulomatosis. J Rheumatol 2007 34 : 1875 81. (Pubitemid 350067649)
57. Booth AD, Wallace S, McEniery CM et al. Inflammation and arterial stiffness in systemic vasculitis: a model of vascular inflammation. Arthritis Rheum 2004 50 : 581 8. (Pubitemid 38198843)
58. Sangle SR, Davies RJ, Mora M, Baron MA, Hughes GR, D'Cruz DP. Ankle-brachial pressure index: a simple tool for assessing cardiovascular risk in patients with systemic vasculitis. Rheumatology (Oxf) 2008 47 : 1058 60.
59. Wung PK, Anderson T, Fontaine KR et al. Effects of glucocorticoids on weight change during the treatment of Wegener's granulomatosis. Arthritis Rheum 2008 59 : 746 53.
60. Glass CK, Witztum JL. Atherosclerosis. The road ahead. Cell 2001 104 : 503 16. (Pubitemid 32201946)
61. Tervaert JW, Kallenberg CG. Cell adhesion molecules in vasculitis. Curr Opin Rheumatol 1997 9 : 16 25. (Pubitemid 27217764)
62. Belizna C, Tervaert JW. Specificity, pathogenecity, and clinical value of antiendothelial cell antibodies. Semin Arthritis Rheum 1997 27 : 98 109. (Pubitemid 27461155)
63. Dhawan V, Mahajan N, Jain S. Role of C-C chemokines in Takayasu's arteritis disease. Int J Cardiol 2006 112 : 105 11. (Pubitemid 44247192)
64. Torheim EA, Yndestad A, Bjerkeli V, Halvorsen B, Aukrust P, Froland SS. Increased expression of chemokines in patients with Wegener's granulomatosis - modulating effects of methylprednisolone in vitro. Clin Exp Immunol 2005 140 : 376 83. (Pubitemid 40559167)
65. Ellingsen T, Elling P, Olson A et al. Monocyte chemoattractant protein 1 (MCP-1) in temporal arteritis and polymyalgia rheumatica. Ann Rheum Dis 2000 59 : 775 80.
66. Wong M, Silverman ED, Fish EN. Evidence for RANTES, monocyte chemotactic protein-1, and macrophage inflammatory protein-1 beta expression in Kawasaki disease. J Rheumatol 1997 24 : 1179 85. (Pubitemid 27250129)
67. Cid MC, Hoffman MP, Hernandez-Rodriguez J et al. Association between increased CCL2 (MCP-1) expression in lesions and persistence of disease activity in giant-cell arteritis. Rheumatology (Oxf) 2006 45 : 1356 63. (Pubitemid 44605469)
68. Antonelli A, Ferri C, Fallahi P et al. CXCL10 and CCL2 serum levels in patients with mixed cryoglobulinaemia and hepatitis C. Dig Liver Dis 2009 41 : 42 8.
69. Ward JR, Wilson HL, Francis SE, Crossman DC, Sabroe I. Translational Mini-Review Series on Immunology of Vascular Disease: Inflammation, infections and Toll-like receptors in cardiovascular disease. Clin Exp Immunol doi: 10.1111/j.1365-2249.2009.03886.x.
70. Tervaert JW. Infections in primary vasculitides. Cleve Clin J Med 2002 69 (Suppl. 2 SII24 6. (Pubitemid 41315549)
71. Compton T, Kurt-Jones EA, Boehme KW et al. Human cytomegalovirus activates inflammatory cytokine responses via CD14 and Toll-like receptor 2. J Virol 2003 77 : 4588 96. (Pubitemid 36402808)
72. van Leeuwen M, Gijbels MJ, Duijvestijn A et al. Accumulation of myeloperoxidase-positive neutrophils in atherosclerotic lesions in LDLR-/- mice. Arterioscler Thromb Vasc Biol 2008 28 : 84 9.
73. Zernecke A, Bot I, Djalali-Talab Y et al. Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis. Circ Res 2008 102 : 209 17.
74. Heeringa P, Huugen D, Tervaert JW. Anti-neutrophil cytoplasmic autoantibodies and leukocyte-endothelial interactions: a sticky connection? Trends Immunol 2005 26 : 561 4. (Pubitemid 41726442)
75. Xiao H, Heeringa P, Liu Z et al. The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies. Am J Pathol 2005 167 : 39 45. (Pubitemid 40884768)
76. Podrez EA, Hoppe G, O'Neil J, Hoff HF. Phospholipids in oxidized LDL not adducted to apoB are recognized by the CD36 scavenger receptor. Free Radic Biol Med 2003 34 : 356 64. (Pubitemid 36120751)
77. Malle E, Marsche G, Arnhold J, Davies MJ. Modification of low-density lipoprotein by myeloperoxidase-derived oxidants and reagent hypochlorous acid. Biochim Biophys Acta 2006 1761 : 392 415. (Pubitemid 43776460)
78. Brennan ML, Hazen SL. Emerging role of myeloperoxidase and oxidant stress markers in cardiovascular risk assessment. Curr Opin Lipidol 2003 14 : 353 9. (Pubitemid 36951900)
79. Meuwese MC, Stroes ES, Hazen SL et al. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol 2007 50 : 159 65. (Pubitemid 47002189)
80. Asselbergs FW, Tervaert JW, Tio RA. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2004 350 : 516 8 author reply: 8.
81. Rutgers A, Heeringa P, Tervaert JW. The role of myeloperoxidase in the pathogenesis of systemic vasculitis. Clin Exp Rheumatol 2003 21 : S55 63. (Pubitemid 38016480)
82. Minota S, Horie S, Yamada A et al. Circulating myeloperoxidase and anti-myeloperoxidase antibody in patients with vasculitis. Scand J Rheumatol 1999 28 : 94 9. (Pubitemid 29173253)
83. Reynolds WF, Stegeman CA, Tervaert JW. 463 G/A myeloperoxidase promoter polymorphism is associated with clinical manifestations and the course of disease in MPO-ANCA-associated vasculitis. Clin Immunol 2002 103 : 154 60. (Pubitemid 34596983)
84. Rajp A, Adu D, Savage CO. Meta-analysis of myeloperoxidase G-463/A polymorphism in anti-neutrophil cytoplasmic autoantibody-positive vasculitis. Clin Exp Immunol 2007 149 : 251 6. (Pubitemid 47063053)
85. Ma-Krupa W, Jeon MS, Spoerl S, Tedder TF, Goronzy JJ, Weyand CM. Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis. J Exp Med 2004 199 : 173 83. (Pubitemid 38129698)
86. Wilde B, Dolff S, Cai X et al. CD4+CD25+ T-cell populations expressing CD134 and GITR are associated with disease activity in patients with Wegener's granulomatosis. Nephrol Dial Transplant 2009 24 : 161 71.
87. Slot MC, Sokolowska MG, Savelkouls KG, Janssen RG, Damoiseaux JG, Cohen Tervaert JW. Immunoregulatory gene polymorphisms are associated with ANCA-related vasculitis. Clin Immunol 2008 128 : 39 45.
88. Liuzzo G, Goronzy JJ, Yang H et al. T-cell proliferation and plaque instability in acute coronary syndromes. Circulation 2000 101 : 2883 8.
89. Lamprecht P, Csernok E, Gross WL. Effector memory T cells as driving force of granuloma formation and autoimmunity in Wegener's granulomatosis. J Intern Med 2006 260 : 187 91. (Pubitemid 44253632)
90. Abdulahad WH, Stegeman CA, van der Geld YM, Doornbos-van der Meer B, Limburg PC, Kallenberg CG. Functional defect of circulating regulatory CD4+ T cells in patients with Wegener's granulomatosis in remission. Arthritis Rheum 2007 56 : 2080 91.
91. Tsurikisawa N, Saito H, Tsuburai T et al. Differences in regulatory T cells between Churg-Strauss syndrome and chronic eosinophilic pneumonia with asthma. J Allergy Clin Immunol 2008 122 : 610 6.
92. Landau DA, Rosenzwajg M, Saadoun D, Trebeden-Negre H, Klatzmann D, Cacoub P. Correlation of clinical and virologic responses to antiviral treatment and regulatory T cell evolution in patients with hepatitis C virus-induced mixed cryoglobulinemia vasculitis. Arthritis Rheum 2008 58 : 2897 907.
93. Swets BP, Brouwer DA, Tervaert JW. Patients with systemic vasculitis have increased levels of autoantibodies against oxidized LDL. Clin Exp Immunol 2001 124 : 163 7. (Pubitemid 32476947)
94. Slot MC, Theunissen R, van Paassen P, Damoiseaux JG, Cohen Tervaert JW. Anti-oxidized low-density lipoprotein antibodies in myeloperoxidase-positive vasculitis patients preferentially recognize hypochlorite-modified low density lipoproteins. Clin Exp Immunol 2007 149 : 257 64. (Pubitemid 47063055)
95. Xu Q, Kiechl S, Mayr M et al. Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis: clinical significance determined in a follow-up study. Circulation 1999 100 : 1169 74. (Pubitemid 30002653)
96. Gruber R, Lederer S, Bechtel U, Lob S, Riethmuller G, Feucht HE. Increased antibody titers against mycobacterial heat-shock protein 65 in patients with vasculitis and arteriosclerosis. Int Arch Allergy Immunol 1996 110 : 95 8. (Pubitemid 26116040)
97. Slot MC, Theunissen R, van Paassen P, Damoiseaux JG, Cohen Tervaert JW. Evaluation of antibodies against human HSP60 in patients with MPO-ANCA associated glomerulonephritis: a cohort study. J Autoimmune Dis 2006 3 : 4. (Pubitemid 44198408)
98. George J, Blank M, Levy Y et al. Differential effects of anti-beta2-glycoprotein I antibodies on endothelial cells and on the manifestations of experimental antiphospholipid syndrome. Circulation 1998 97 : 900 6. (Pubitemid 28113929)
99. George J, Harats D, Gilburd B et al. Adoptive transfer of beta(2)-glycoprotein I-reactive lymphocytes enhances early atherosclerosis in LDL receptor-deficient mice. Circulation 2000 102 : 1822 7.
100. Espinosa G, Tassies D, Font J et al. Antiphospholipid antibodies and thrombophilic factors in giant cell arteritis. Semin Arthritis Rheum 2001 31 : 12 20. (Pubitemid 32756168)
101. Sebastian JK, Voetsch B, Stone JH et al. The frequency of anticardiolipin antibodies and genetic mutations associated with hypercoagulability among patients with Wegener's granulomatosis with and without history of a thrombotic event. J Rheumatol 2007 34 : 2446 50. (Pubitemid 350230669)